Sublime

Strategies to improve the systemic distribution of siRNA drugs and promote efficacy in tissues beyond the liver include conjugation to lipids or targeting entities such as antibodies - find out more in this Review https://t.co/3XTYd2SBB0 https://t.co/7NtiPFYcYO

Looks like $TMO might be buying this thing.... must be really going for it in clinical CRO biz. Makes sense because a lot of the smaller players ( $SYNH and smaller) are struggling to stay afloat. Casper probably seeing a huge opening as things normalize. https://t.co/a7SeKdOSt9

The biotech report that @TimOpler's team at Stifel put out this afternoon is a banger. Some slides on China's impact to $XBI. 1/3 of external molecules brought in by big pharma are now coming from China (from 0 in 2019). https://t.co/sRcy5bZ5Ky

With 124 drugs in development, over 35% drugs are GIP/GLP glucagon receptor agonists and 46% are orals $XBI $LLY $NVO https://t.co/GOpkG1kwW4

Royalty Pharma is a fascinating business. The name pretty much explains the business model -- they purchase royalty streams from academia, biotech, and pharma companies. It's, unsurprisingly, insane profitable. 63% EBIT margins and 127% operating cash flow... See more